David L. Lowrance, the Chief Financial Officer of Savara Inc. (NASDAQ: SVRA), executed a complex series of stock transactions on June 22, 2026, involving both the sale and acquisition of the company's common shares. On that date, Lowrance sold 394,528 shares of SVRA stock. The transaction was executed at prices ranging between $5.54 and $5.78 per share, resulting in a total sale value of approximately $2.24 million. This divestment occurs against the backdrop of a notable performance trajectory for the biotechnology company, which has generated a 163% return over the preceding twelve months, according to InvestingPro data.
Concurrent with the sales, Lowrance acquired 580,187 additional shares of Savara common stock through the exercise of stock options. These newly acquired shares were purchased at exercise prices ranging from $1.11 to $4.45, totaling approximately $1.02 million. To manage the associated tax liabilities from these option exercises, 185,659 shares were subsequently disposed of at a price of $5.50 per share, further contributing to a total transaction value of roughly $1.02 million for the tax-related portion.
Following these reported activities, Lowrance's direct ownership position in Savara Inc. stands at 536,032 shares. At the time of reporting, the company's stock was trading at $5.69, supporting a market capitalization of $1.43 billion. The financial data underscores the active management of executive holdings within the context of the company's broader strategic developments.
In parallel with the insider activity, Savara announced significant corporate governance and leadership changes following its annual shareholder meeting. Shareholders voted to approve an amendment to the Certificate of Incorporation, effectively doubling the authorized number of common stock shares from 300 million to 600 million. This amendment was formalized upon filing with the Secretary of State of Delaware.
A critical component of the recent announcements involves a leadership transition within the executive suite. Savara confirmed that David Lowrance will step down from his position as Chief Financial and Administrative Officer effective July 15, 2026, citing health-related reasons. Robert Lutz, who currently serves as the Chief Operating Officer, will assume the additional responsibilities of Chief Financial Officer. This transition marks a shift in the financial oversight structure of the biotech firm.
Furthermore, the company disclosed clinical trial results at the American Thoracic Society International Conference. Data from the IMPALA-2 Phase 3 clinical trial, which enrolled 164 patients diagnosed with autoimmune pulmonary alveolar proteinosis, indicated that molgramostim improved both exercise distance and duration. These developments highlight ongoing operational changes and clinical progress within the organization.